<DOC>
	<DOCNO>NCT00810303</DOCNO>
	<brief_summary>The purpose study evaluate effect chronic co-medication efavirenz pharmacokinetics sterol-lowering effect ezetimibe steady-state healthy subject genotyped ABCB1 , ABCC2 , CYP2B6 UGT1A1 .</brief_summary>
	<brief_title>Pharmacokinetic Pharmacodynamic Interactions Between Cholesterol-lowering Ezetimibe Non-nucleoside Reverse Transcriptase Inhibitor Efavirenz During Chronic Treatment Healthy Volunteers With Reference Intestinal Expression CYP3A4 , UGT1A1 , ABCB1 ABCC2</brief_title>
	<detailed_description />
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>age : 18 45 year sex : male female ethnic origin : Caucasian body weight : 19 27 kg/mÂ² good health evidence result clinical examination , ECG , laboratory checkup , judge clinical investigator differ clinical relevant way normal state write informed consent exist cardiac haematological disease and/or pathological finding , might interfere drug 's safety , tolerability , absorption and/or pharmacokinetics exist hepatic renal disease and/or pathological finding , might interfere drug 's safety , tolerability , absorption and/or pharmacokinetics exist gastrointestinal disease and/or pathological finding , might interfere drug 's safety , tolerability , absorption and/or pharmacokinetics acute chronic disease could affect drug absorption metabolism history serious psychological disorder drug alcohol dependence positive drug alcohol screen smoker 10 cigarette per day positive antiHIVtest , HBsAgtest antiHCVtest volunteer diet could affect pharmacokinetics drug heavy tea coffee drinker ( 1L per day ) lactation pregnancy test positive perform volunteer suspect know follow instruction volunteer unable understand write verbal instruction , particular regard risk inconvenience expose result participation study volunteer liable orthostatic dysregulation , fainting , blackouts blood donation blood loss 400 ml within last 12 week prior start study participation clinical trial last 3 month prior start study le 14 day last acute disease systemically available medication within 4 week prior intend first administration unless terminal elimination halflife complete elimination body assume drug and/or primary metabolite ( except oral contraceptive ) repeat use drug last 4 week prior intend first administration , influence hepatic biotransformation ( e.g . barbiturate , cimetidine , phenytoin , rifampicin ) repeat use drug last 2 week prior intend first administration affect absorption ( e.g . laxative , metoclopramide , loperamide , antacid , H2receptor antagonists ) intake grapefruit contain food beverage within 7 day prior administration know allergic reaction active ingredient use constituent pharmaceutical preparation subject severe allergy multiple drug allergy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2010</verification_date>
</DOC>